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Abstract
In the context of recently emerged novel influenza strains through reassortment, avian influenza subtypes such as H5N1,
H7N7, H7N2, H7N3 and H9N2 pose a constant threat in terms of their adaptation to the human host. Among these
subtypes, it was recently demonstrated that mutations in H5 and H9 hemagglutinin (HA) in the context of lab-generated
reassorted viruses conferred aerosol transmissibility in ferrets (a property shared by human adapted viruses). We previously
demonstrated that the quantitative binding affinity of HA to a2R6 sialylated glycans (human receptors) is one of the
important factors governing human adaptation of HA. Although the H7 subtype has infected humans causing varied clinical
outcomes from mild conjunctivitis to severe respiratory illnesses, it is not clear where the HA of these subtypes stand in
regard to human adaptation since its binding affinity to glycan receptors has not yet been quantified. In this study, we have
quantitatively characterized the glycan receptor-binding specificity of HAs from representative strains of Eurasian (H7N7)
and North American (H7N2) lineages that have caused human infection. Furthermore, we have demonstrated for the first
time that two specific mutations; Gln226RLeu and Gly228RSer in glycan receptor-binding site of H7 HA substantially
increase its binding affinity to human receptor. Our findings contribute to a framework for monitoring the evolution of H7
HA to be able to adapt to human host.
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Introduction
Avian influenza virus subtypes known to infect and cause
disease in humans include H5N1, H7N7, H7N2, H7N3 and
H9N2 strains. These viruses circulate in domestic poultry but have
not yet adapted to the human host to establish sustained airborne
human-to-human transmission capabilities [1]. One of the
characteristic features of human-adapted subtypes such as
H1N1, H2N2 and H3N2 is the ability of their viral surface
glycoprotein hemagglutinin (HA) to bind preferentially to a2R6
sialylated glycan receptors (or human receptors) that are predomi-
nantly expressed in the human upper respiratory epithelium. The
HA of influenza viruses isolated from avian species typically binds
to a2R3 sialylated glycans (or avian receptors) [2]. Therefore, the
gain in the ability of HA from an avian isolate (such as H5, H7,
H9, etc.) to preferentially bind to human receptors (high relative
binding affinity to human receptor over avian receptor) is
implicated as one of the important factors for the human
adaptation of the virus [3]. In the past few years, novel influenza
strains such as 2009 H1N1 and 2010 H3N2 that naturally
emerged from multiple reassortment of viral gene segments
between avian, swine and human isolates were able to successfully
adapt to human host [4,5]. In the context of these novel strains,
the avian influenza subtypes pose a significant threat of human
adaptation [1]. With the human population predominantly naı¨ve
to these avian influenza antigens, constant surveillance with
particular focus on molecular changes geared towards human host
adaptation becomes vital in this era of pandemics [6].
Specific mutations in glycan-receptor binding site (RBS) of H5
and H9 HAs have been shown to correlate with respiratory droplet
transmissibility of laboratory-generated reassorted viruses posses-
sing either of these mutant HAs (and internal genes from human-
adapted virus) in a ferret animal model [7–10]. Aerosol trans-
missibility in ferrets, a hallmark property of human-adapted
viruses, has been shown to correlate with specificity and
quantitative affinity of viral HA binding to human receptors
[11–13]. In fact a single amino acid mutation Gln226RLeu in H2
HA completely shifts its receptor binding preference from avian to
human receptors and confers airborne viral transmission in ferrets
[14]. Studies on H7 subtype have thus far focused on specific
H7N7 and H7N2 strains isolated from infected patients in Eurasia
and North America respectively (Figure S1). The H7N7 strains
were isolated from two patients with very different clinical
conditions during a local highly pathogenic outbreak in the
Netherlands in 2003 [15]. One of the strains was isolated from
a patient with a conjunctivitis infection (A/Netherlands/230/03
referred to henceforth as CC); which is typical of H7 human
infection, and the other was isolated from a patient with acute
respiratory illness that eventually resulted in fatality (A/Nether-
lands/219/03 henceforth referred to as FC); which was the first of
its kind. The HAs from both CC and FC comprise of the polybasic
sequence between HA1 and HA2 analogous to the highly
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pathogenic H5N1. The RBS of CC and FC HAs differs by a single
amino acid substitution in position 135 (H3 numbering), which is
Ala in CC but Thr in FC (Figure S1). The presence of Thr in 135
in FC introduces a glycosylation sequon at Asn-133 [16–18].
The H7N2 strain A/New York/107/03 or NY/107 was
isolated from a single human case with respiratory infection
[15]. The NY/107 HA does not possess the HA1-HA2 polybasic
sequence, which is typically associated with high pathogenicity. A
dramatically unique feature of NY/107 HA is the complete
deletion of the 220-loop region in the RBS (Figure S1), which
plays a key role in governing glycan receptor-binding specificity of
HA [19].
The glycan receptor-binding properties of CC, FC and NY/107
HAS have been characterized by screening the HAs and whole
viruses on glycan array platform [20–23]. These screening assays
provide an overall readout in terms of the number and different
types of avian and human receptors that bind to the HA (or virus)
when analyzed at a high protein concentration or virus titer. A
limitation of such screening studies is that they do not quantify the
relative binding affinities of HA to avian versus human receptor. It
is important to quantify the nuances in relative binding affinities in
order to understand how molecular changes in the HA such as
deletion of 220-loop and differences in glycosylation at Asn-133
impinge on glycan receptor binding. We have previously
demonstrated that a change in glycosylation at a single site subtly
alters human receptor-binding affinity of the pandemic 1918
H1N1 HA [24]. Furthermore we have demonstrated that
quantitative parameters derived from a dose-dependent binding
of HA to representative human and avian receptors correlated
with the respiratory droplet transmissibility of the virus [11–13].
In this study, we quantify the relative human and avian
receptor-binding affinity of CC, FC and NY/107 HA. We also
characterized the effect of altering glycosylation at Asn-133 on
NY/107 HA in the context of the deletion of 220-loop on the
relative glycan-receptor binding affinities of this HA. Finally we
introduced the Gln226RLeu and Gly228RSer double mutation
in the RBS of FC and CC HAs since the Leu-226/Ser-228
combination in the RBS is a hallmark of all the human-adapted
H3N2 HAs (belong to the same group 2 clade as H7) and
characterize the effect of these mutations on quantitative glycan
receptor-binding affinity of these HAs. Our study provides
important biochemical insights for monitoring the evolution of
H7 HAs as they continue to circulate in avian species and cause
sporadic human outbreaks and also pose a constant threat of
adapting to human host through reassortment.
Results
FC, CC and NY/107 HA were recombinantly expressed as
described earlier [12,13]. Given that FC and CC HA differ by
a single amino acid change at RBS, CC HA was generated by
introducing a Thr135RAla mutation through site-directed
mutagenesis. The wild type and mutant HAs were analyzed on
a glycan array platform in a dose-dependent fashion and an
apparent binding parameter Kd’ was calculated to quantify the
relative binding affinities as described earlier [12,13] (see
Methods).
Quantitative glycan-receptor binding affinities of H7N7
CC and FC HAs
FCHA exclusively bound to the avian receptors, 39 SLN, 39SLN-
LN and 39 SLN-LN-LN (Kd’ ,25 pM; based on 39SLN-LN and
39SLN-LN-LN;Kd values were similar for binding for both glycans)
(Figure 1A). The apparent binding affinity of FC HA to avian
receptors was comparable to HAs from avian H2N2 and H5N1
strains analyzed in a similar fashion previously [12,13]. The HA
from CC which lacks glycosylation at Asn-133 also showed
predominant binding to avian receptors (Kd’,65 pM) (based on
39 SLN-LN 39SLN-LN-LN binding; Kd values were similar for
binding for both glycans) (Figure 1B). CC showed observable
binding to human receptors in a dose dependent fashion although at
several orders of magnitude lower than avian receptor binding (Kd’
was not calculated since saturation was not reached in the
concentration window for avian receptor binding). The presence
of glycosylation at Asn-133 therefore appears to increase avian
receptor specificity for H7N7 HAs. On the other hand lack of
glycosylation at this site appears to increase propensity for binding to
human receptors.
Quantitative glycan-receptor binding affinities of H7N2
NY/107 HA
As mentioned earlier, NY/107 HA has a deletion of 8 amino
acids in the 220-loop (which is almost the entire loop). The glycan
array screening of NY/107 carried out previously showed that this
HA shows mixed binding to both avian and human receptors [20].
X-ray crystallography studies of NY/107 HA complexed with
avian and human receptors have been solved. The binding of NY/
107 HA to avian receptor is clearly observed in terms of resolving
the coordinates of the sugar units in the RBS in the X-ray crystal
structure [19]. On the other hand, much poorer electron density
map and fewer interactions were observed for human receptor in
RBS of NY/107 HA [19]. These structural observations do not
fully explain the observed mixed binding to both avian and human
receptors by this HA.
NY/107 HA showed predominant high affinity binding
(Kd’,63 pM) (Based on 39SLN-LN) to avian receptors and
a significantly lower binding to human receptors in our dose-
dependent binding analysis (Figure 1C). The orders of magnitude
higher relative affinity for binding to avian over human receptors
by NY/107 HA is consistent with the observed interactions in the
X-ray co-crystal structure of HA-glycan complexes [19]. Given
that glycosylation at Asn-133 appeared to improve specificity for
avian receptors in the H7N7 FC HA, we wanted to test if a similar
effect was seen in the case of NY/107 HA specifically in the
context of the deletion of the 220-loop. Therefore the
Ala135RThr mutation was introduced on NY/107 HA and this
mutant HA showed the identical binding profile in a dose-
dependent fashion as that of the wild type HA (Figure 1D). This
result suggested that the glycosylation at Asn-133 is not likely to
affect glycan-receptor binding of H7N2 HAs in which the 220-
loop is deleted like in the case of NY/107 HA.
Quantitative glycan-binding affinity of H7N7 HAs double
Gln226RLeu/Gly228RSer mutations
A double Gln226RLeu/Gly228RSer mutations has quantita-
tively switched the glycan receptor binding specificity and affinity
from avian receptor to human receptors for H3 and H2 HAs [12].
However such a double mutation has not quantitatively switched or
increased binding of avian H5 HAs to human receptors [25,26].
Given that H7 HA belongs to the same phylogenetic clade 2 as H3
HA, we wanted to evaluate the effect of the double mutation on the
H7N7 HAs (given that NY/107 HA does not have the 220 loop).
Introducing the double Gln226RLeu/Gly228RSer mutations
on FC (mFC:LS) and CC (mCC:LS) resulted in binding to both
avian and human receptors. The human receptor binding affinity
(Kd’,1 nM) (Based on 69 SLNLN binding) of mFC:LS and
mCC:LS HAs was orders of magnitude higher (Figure 2A and 2B)
Glycan-Receptor Binding of H7 Hemagglutinin
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and the human receptor binding observed for H7N7 CC and NY/
107 HAs based on the quantitative dose-dependent binding assay.
Interestingly the avian receptor binding affinity of mFC:LS
(Kd,70 pM) (based on 39 SLN-LN) and mCC:LS (for
Kd,225 pM) (based on 39SLN-LN) was lower than that of their
respective wild type HAs (Figure 1A and 1B).
The crystal structure and co-crystal structures of FC in complex
with human and avian receptor were solved recently [23]. These
structures permitted comparison of molecular contacts of FC –
avian receptor and mFC:LS – human receptor complexes
(Figure 3). While Gln-226 of FC makes optimal contact with
glycosidic oxygen atom of Neu5Aca2RGal motif of the avian
receptor, Leu-226 in the RBS of mFC:LS is positioned to make
optimal contacts with C-6 atom of Gal sugar in the terminal
Neu5Aca2R6Gal-motif of the human receptor. This observation
offers an explanation the gain in human receptor binding of the
double mutants. On the other hand Ser-228 of mFC:LS is
positioned to make contact with both avian and human receptor.
Therefore the loss in binding to avian receptor by Gln-226RLeu
mutation is compensated in part by binding of Ser-228 to avian
receptor. This structural observation is consistent with the
observed avian receptor-binding of the double mutants.
Binding of H7 HAs to human respiratory tissues
To compare observed binding specificities ofH7HAs on the array
with their binding to physiological glycan receptors, human tracheal
(apical surface predominantly comprises of human receptors) and
alveolar (predominantly comprises of avian receptors) sections were
stained using representative wild type and the mutant HA with the
double mutation. mFC: LS showed extensive staining of apical
surface of the tracheal epithelium where human receptors are
predominantly expressed (Figure 4A). Specifically it also pre-
dominantly stained what appear to be non-ciliated (goblet) cells.
Extensive staining of goblet cells is a property that we have
previously observed to be shared by human adapted HAs
[12,13,27]. The staining of tracheal epithelium by the mutant HA
is consistent with its observed human receptor-binding in the glycan
array analysis. On the other hand, the wild-type FC HA showed
minimal staining of the apical surface of the human tracheal
epithelium (Figure 4B) consistent with its minimal human-receptor
binding on the glycan array. Both the wild-type FC and mutant
mFC:LS HAs showed extensive staining of the human alveolar
section, which predominantly expresses a2R3 sialylated glycans
(Figure 4C and 4D). This staining pattern is consistent with the
binding of these HAs to the avian receptors on the glycan array.
Figure 1. Glycan receptor-binding specificity of FC, CC, NY/107 and mNY/107:A135T HA. A, shows dose-dependent direct glycan array
binding of FC HA. Specific high affinity binding to avian receptors (39 SLN, 39 SLNLN and 39 SLNLNLN) and no binding to human receptors is observed.
B, shows dose-dependent direct glycan array binding of CC HA. High affinity binding to avian receptors is observed. In comparison with FC, there is
observable binding to human receptors (69SLN-LN and 69SLN) albeit at orders of magnitude lower affinity than binding to avian receptors. C, shows
dose-dependent direct glycan array binding of NY/107 HA. High affinity binding to avian receptors (39SLN-LN and 39SLN-LN-LN) is observed with
binding affinity for 39SLN lower than that of FC and CC HAs. Binding to human receptor is observed but at much lower affinity (by orders of
magnitude) than binding to avian receptors. D, shows dose-dependent direct glycan array binding of mutant mNY/107:A135T HA. Introduction of
glycosylation sequon at Asn-133 does not seem to alter binding of this mutant HA in relation to the wild type.
doi:10.1371/journal.pone.0049597.g001
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Discussion
The functions of HA in terms of glycan-receptor binding
specificity and cleavage sequence for membrane fusion is among
the key factors that contribute to the pathogenicity, severity of
infection and transmissibility of influenza A virus. In this study we
characterized in a quantitative fashion, the relative binding
affinities of H7 HA to avian and human receptors given that
some H7 strains especially from the Eurasian lineage are highly
pathogenic and have caused human infections. To our knowledge,
such a quantitative description of glycan-binding properties of H7
HA has not been reported earlier.
The FC, CC and NY/107 strains were also previously analyzed
for their ability to transmit in the ferret animal model NY/107 and
the highly pathogenic CC strain showed some transmission via
direct contact, however the other highly pathogenic strain isolated
from fatal case did not show any transmission. None of the viruses
transmitted via respiratory droplets. Since we previously demon-
strated that the human receptor-binding specificity and affinity
correlates with respiratory droplet transmissibility in ferrets, we
sought to investigate any potential mutations that would signifi-
cantly increase the human-receptor binding of H7 HAs in this
study. We demonstrated that the double Gln226RLeu/Gly228R
Ser mutation (hallmark changes for human adaptation of H3 and
H2 HA) dramatically increased human receptor-binding affinity of
FC and CC HA. This study is therefore the first to report
mutations in H7 HA that quantitatively increase its human
receptor-binding affinity. Although none of the H7 HA sequences
(obtained from NCBI flu database: http://www.ncbi.nlm.nih.gov/
genomes/FLU/FLU.html) have Leu-226 and Ser-228, our study
demonstrates that these mutations are easily accommodated in the
H7 RBS to substantially increase binding to human receptors.
Figure 2. Glycan receptor-binding specificity of Gln226RLeu/Gly228RSer mutant of FC and CC. A and B, respectively show dose-
dependent direct glycan array binding of mFC: LS and mCC: LS mutant HAs. The double mutation leads to a substantial increase in human-receptor
binding signals to a level that allowed calculation of apparent binding affinity parameter Kd’. The double mutation also lowers the avian-receptor
binding affinity of mutant HAs relative to the corresponding wild-type HAs.
doi:10.1371/journal.pone.0049597.g002
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Furthermore the Gln-226RLeu mutation has been observed in
the H9 avian isolates. Therefore, it is important to monitor the
evolution of current H7 HAs from the standpoint of their ability to
acquire these mutations.
Although the doublemutation increased human receptor binding
of FC and CC HAs, the binding affinity of this HA to human
receptor was still lower relative to avian receptor. This is not a typical
characteristic of human-adapted HAs such as prototypic pandemic
1918 H1N1 and 1958 H2N2 HAs. However a natural variant of
1918H1N1HA isolated fromhumanswhich has a single amino acid
mutation in the RBS (A/New York/1/18) shows a similar relative
binding affinity as that of the mCC:LS and mFC: LS HAs. This
observation warrants further investigation of the aerosol trans-
mission in ferrets of reassorted viruses carrying these mutant H7
HAs in context of other human adapted genes similar to the previous
studies carried out for H9 and H5 subtypes [7,8].
In summary our results highlight the nuances in biochemical
glycan-binding binding affinities of H7 HAs from two very
different lineages and also show mutations in the Eurasian lineage
that quantitatively increase their human receptor-binding affinity.
Our studies would pave way for investigating the effect of these
changes in contributing to the human adaptation of H7 HA based
on additional ferret transmission studies that need to be performed
on viruses carrying these mutant HAs.
Materials and Methods
Cloning, baculovirus synthesis, expression and
purification of HA
Briefly, recombinant baculoviruses with FC or NY/107 gene
and mutants off of each background, were used to infect (MOI= 1)
suspension cultures of Sf9 cells (Invitrogen, Carlsbad, CA) cultured
in BD Baculogold Max-XP SFM (BD Biosciences, San Jose, CA).
The infection was monitored and the conditioned media was
harvested 3–4 days post-infection. The soluble HA from the
harvested conditioned media was purified using Nickel affinity
chromatography (HisTrap HP columns, GE Healthcare, Piscat-
away, NJ). Eluting fractions containing HA were pooled,
concentrated and buffer exchanged into 1X PBS pH 8.0 (Gibco)
using 100K MWCO spin columns (Millipore, Billerica, MA). The
purified protein was quantified using BCA method (Pierce). N-
glycosylation is known to play an important role in folding and
maintaining the three dimensional structure of HA [12]. In order
to ascertain that mutation at position 143 did not affect protein
stability circular dichroism analysis of the all wild type and mutant
HAs was performed alongside H2 HA, A/Albany/6/58 (Alb58)
isolated from the 1957–58 pandemic. The circular dichroism
spectra of all the mutant proteins were generated between 190 nm
and 280 nm. All the mutants showed similar circular dichroism
spectral signatures as that of their wild-type counterparts and
Alb58, a H2N2 HA (A/Albany/6/58) (Figure S2).
Dose dependent direct binding of FC, NY/107 and
mutant HAs
To investigate the multivalent HA-glycan interactions a strepta-
vidin plate array comprising of representative biotinylated a2R3
and a2R6 sialylated glycans was used as described previously
[13]. 39SLN, 39SLN-LN, 39SLN-LN-LN are representative avian
receptors. 69SLN and 69SLN-LN are representative human
receptors (see Table S1). The biotinylated glycans were obtained
from the Consortium of Functional Glycomics through their
resource request program. Streptavidin-coated High Binding
Capacity 384-well plates (Pierce) were loaded to the full capacity
of each well by incubating the well with 50 ml of 2.4 mM of
biotinylated glycans overnight at 4uC. Excess glycans were
removed through extensive washing with PBS. The trimeric HA
unit comprises of three HA monomers (and hence three RBS, one
for each monomer). The spatial arrangement of the biotinylated
glycans in the wells of the streptavidin plate array favors binding to
only one of the three HA monomers in the trimeric HA unit.
Therefore in order to specifically enhance the multivalency in the
HA-glycan interactions, the recombinant HA proteins were pre-
Figure 3. Structural complexes of FC – avian receptor and
mFC:LS – human receptor. A, shows the structural complex of RBS
of FC HA with avian receptor derived from the X-ray co-crystal structure
of this complex (PDB ID: 4DJ7). B, shows structural complex of RBS of
mFC:LS HA with human receptor derived based on homology-model of
mFC:LS (generated using automated mode in Swiss Model: http://
swissmodel.expasy.org/). The coordinates of the human receptor were
obtained from PDB ID: 2WR7. The mFC:LS human receptor structural
complex was obtained by superimposing the HA1 domain (bound to
this receptor) of 2WR7 with that of mFC:LS HA1 homology model
followed by subsequent energy minimization. The critical contacts
made by Gln-226 (in FC HA) and Leu-226 (in mFC:LS HA) with glycan
receptor is shown using a dotted line.
doi:10.1371/journal.pone.0049597.g003
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complexed with the primary and secondary antibodies in the
molar ratio of 421 (HA: primary: secondary). The identical
arrangement of 4 trimeric HA units in the pre-complex for all the
HAs permit comparison between their glycan binding affinities. A
stock solution containing appropriate amounts of Histidine tagged
HA protein, primary antibody (Mouse anti 6X His tag IgG) and
secondary antibody (HRP conjugated goat anti Mouse IgG
(Santacruz Biotechnology) in the ratio 4:2:1 and incubated on
ice for 20 min. Appropriate amounts of pre-complexed stock HA
were diluted to 250 ml with 1% BSA in PBS. 50 ml of this pre-
complexed HA was added to each of the glycan-coated wells and
incubated at room temperature for 2 hours followed by the above
wash steps. The binding signal was determined based on HRP
activity using Amplex Red Peroxidase Assay (Invitrogen, CA)
according to the manufacturer’s instructions. The experiments
were done in triplicate. Minimal binding signals were observed in
the negative controls including binding of pre-complexed unit to
wells without glycans and binding of the antibodies alone to the
wells with glycans. The binding parameters, cooperativity (n) and
apparent binding constant (Kd’), for HA-glycan binding were
calculated by fitting the average binding signal value (from the
triplicate analysis) and the HA concentration to the linearized
form of the Hill equation:
log
y
1{y
 
~n  log HA½ ð Þ{ log K 0d
 
where y is the fractional saturation (average binding signal/
maximum observed binding signal). In order to compare Kd’
values, the values reported in this study correspond to the
appropriate representative avian (39SLN-LN or 39SLN-LN-LN)
and human (69SLN-LN) receptor that gave the best fit to the above
equation and the same slope value (n,1.3).
Binding of recombinant FC and mFC: LS HAs to human
tracheal and alveolar tissue sections
Paraffinized human tracheal (US BioChain) tissue sections were
deparaffinized, rehydrated and incubated with 1% BSA in PBS for
30 minutes to prevent non-specific binding. HAwas pre-complexed
with primary antibody (mouse anti 6X His tag, Abcam) and
secondary antibody (Alexa fluor 488 goat anti mouse, Invitrogen) in
a molar ratio of 4:2:1, respectively, for 20 minutes on ice. The tissue
binding was performed over differentHA concentrations by diluting
Figure 4. Tissue binding specificity of FC and mFC:LS for human tracheal and alveolar sections. A, Extensive staining of apical surface of
human tracheal epithelia for the mFC: LS (green) against propidium iodide staining (in red) is observed. Bright staining of what appears to be goblet
cells (inset at 20x magnification; indicated by white arrow) by this mutant HA resembles a similar pattern that was previously observed with 1918
H1N1 and 1958 H2N2 HAs. B, Shows minimal to no staining of apical surface of tracheal section by FC consistent with its low binding to human
receptors on glycan array. C and D respectively show intense staining of alveolar section by mFC:LS and FC consistent with their high affinity binding
to avian receptors.
doi:10.1371/journal.pone.0049597.g004
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the pre-complexed HA in 1% BSA-PBS. Tissue sections were then
incubated with the HA-antibody complexes for 3 hours at RT. The
tissue sections were counterstained by propidium iodide (Invitrogen;
1100 in TBST). The tissue sections were mounted and then viewed
under a confocal microscope (Zeiss LSM 700 laser scanning
confocal microscopy). Sialic-acid specific binding of HAs to tissue
sections was confirmed by loss of staining after pre-treatment with
Sialidase A (recombinant from Arthrobacter ureafaciens, Prozyme), This
enzyme has been demonstrated to cleave the terminal Neu5Ac from
bothNeu5Aca2R3Gal andNeu5Aca2R6Galmotifs. In the case of
sialidase pretreatment, tissue sections were incubated with 0.2 units
of Sialidase A for 3 hours at 37uC prior to incubation with the
proteins.
Supporting Information
Figure S1 Sequence Alignment of glycan-receptor bind-
ing site of H7 HAs. Shown in the figure is the sequene
alignment of HAs used in this study. The tk_Italy_H7N3 HA is
also included since its X-ray crystal structure has been solved. The
residue positions 133, 135, 226 and 228 are marked given that
their properties have been modified throught mutagenesis in this
study. The deletion of the 220-loop in NY/107 HA is also shown.
(PNG)
Figure S2 Circular Dichroism Analysis of H7 wild type
and mutant HAs used in the study. Circular dichroism
spectra for FC, CC, NY/107, mFC: Q226L, mCC: Q226L and
Alb58 (A/Albany/6/58; H2N2 HA) are shown as indicated in the
legend. All examined HAs show similar spectral signatures
indicative of no general misfolding due to amino acid substitutions.
(TIF)
Table S1 Expanded nomenclature of glycans used in the
glycan array. Table shows expanded nomenclature of the
representative avian and human receptors used in glycan array.
The monosaccharide key for the sugars is as follows – Neu5Ac: N-
acetyl D-neuraminic acid; Gal: D-galactose; GlcNAc: N-acetyl D-
glucosamine. a/b: anomeric configuration of the pyranose sugars.
All the sugars are linked via a spacer to biotin (-Sp-LC-LC-Biotin
as described in http://www.functionalglycomics.org/static/
consortium/resources/resourcecored5.shtml).
(PDF)
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